Parikh M S, Fielding G A, Ren C J
Department of Surgery, New York University School of Medicine, 530 First Avenue, Suite 10S, New York, NY 10016, USA.
Surg Endosc. 2005 Dec;19(12):1631-5. doi: 10.1007/s00464-005-0302-7. Epub 2005 Oct 17.
Laparoscopic adjustable gastric band (LAGB) has consistently been shown to be a safe and effective treatment for morbid obesity, especially in Europe and Australia. Data from the U.S. regarding the LAGB has been insufficient. This study reveals our experience with 749 primary LAGB over a 3-year period in a U.S. university teaching hospital.
All data was prospectively collected and entered into an electronic registry. Characteristics evaluated for this study include preoperative age, BMI, gender, race, conversion rate, operative time, hospital stay, percent excess weight loss (%EWL) and postoperative complications. Annual esophagrams were performed
From July 2001 through September 2004, 749 patients (531 females, 218 males) underwent LAGB for the treatment of morbid obesity. There were 630 Caucasians, 61 African-Americans, and 49 Latin Americans, with a mean age of 42.3 (range 18, 72 years) and mean BMI of 46.0 +/- 7.0 (range 35, 91.5 kg/m(2)). There was one conversion to open (0.1%). Median operative time and hospital stay were 60 minutes and 23 hours, respectively. The mean %EWL at 1 year, 2 years, and 3 years was 44.4 (+/-17.8), 51.8 (+/-20.9), and 52.0 (+/-19.6), respectively. There were no mortalities. Postoperative complications occurred in 12.8% of patients: 1.5% acute postoperative band obstruction, 0.9% wound infection, 2.9% gastric prolapse ("slip"), 2.0% concentric pouch dilatation (without slip), 0.8% aspiration pneumonia, 2.4% port/tubing problems, 0.3% severe esophageal dilatation/dysmotility (reversible), and 1.5% overall band removal.
These American results substantiate the data from abroad that LAGB is a safe and effective treatment for morbid obesity.
腹腔镜可调节胃束带术（LAGB）一直被证明是治疗病态肥胖的一种安全有效的方法，尤其是在欧洲和澳大利亚。美国关于LAGB的数据一直不足。本研究揭示了我们在美国一所大学教学医院3年期间对749例原发性LAGB的经验。
所有数据均前瞻性收集并录入电子登记系统。本研究评估的特征包括术前年龄、体重指数（BMI）、性别、种族、转换率、手术时间、住院时间、超重减轻百分比（%EWL）和术后并发症。每年进行食管造影检查。
从2001年7月至2004年9月，749例患者（531例女性，218例男性）接受LAGB治疗病态肥胖。其中有630例白种人、61例非裔美国人、49例拉丁美洲人，平均年龄42.3岁（范围18至72岁），平均BMI为46.0±7.0（范围35至91.5kg/m²）。有1例转为开放手术（0.1%）。中位手术时间和住院时间分别为60分钟和23小时。1年、2年和3年时的平均%EWL分别为44.4（±17.8）、51.8（±20.9）和52.0（±19.6）。无死亡病例。12.8%的患者发生术后并发症：1.5%为术后急性束带梗阻，0.9%为伤口感染，2.9%为胃脱垂（“滑脱”），2.0%为同心袋扩张（无滑脱），0.8%为吸入性肺炎，2.4%为端口/管道问题，0.3%为严重食管扩张/运动障碍（可逆），1.5%为束带整体移除。
这些美国的研究结果证实了国外的数据，即LAGB是治疗病态肥胖的一种安全有效的方法。
